Literature DB >> 22417714

Medicare part D research and policy highlights, 2012: impact and insights.

Denys T Lau1, JoAnn Stubbings.   

Abstract

BACKGROUND: In the 6 years since the implementation of Medicare Part D in the United States, the program has been reported to improve quality, offer better beneficiary protections, and lower drug costs.
OBJECTIVE: The purpose of this article was to highlight the latest key peer-reviewed research findings on Medicare Part D and major public policy initiatives for Part D for 2012.
METHODS: PubMed was searched for studies on Medicare Part D published in 2011 in biomedical/scientific, peer-reviewed, English-language journals. For the policy update, sources included the Federal Register, the Medicare Prescription Drug Benefit Manual, the 2012 Final Call Letter, and guidance from the Centers for Medicare and Medicaid Services.
RESULTS: Medicare Part D has been associated with increased medication utilization, reduced out-of-pocket expenditures, and an overall decrease in cost-related non-adherence and nonpersistence. Its impact on reduction in non-drug utilization of health services has been more apparent after the transition year in 2006 and among subsets of Medicare beneficiaries. Recent policy changes promise to make Part D more user-friendly, simplify choice, and offer greater protection to beneficiaries. The coverage gap will phase out by 2020. Both the quality rating system for prescription drug plans and medication therapy management programs were enhanced.
CONCLUSIONS: Although Part D was designed to improve drug benefits, improvements may be needed in plan selection and simplification, quality assessment (especially with regard to long-term impact and health outcomes), evidence-based improvements in medication therapy management, and disparities among priority subpopulations. Medicare Parts A, B, and D could be coordinated to offset costs by increasing medication expenses and decreasing expenses for nonprescription medical services, thereby improving the overall cost-effectiveness of the Medicare program.
Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22417714      PMCID: PMC3392198          DOI: 10.1016/j.clinthera.2012.02.012

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  32 in total

1.  Medicare Part D policy update and implications for 2010.

Authors:  Ronnie J DePue; JoAnn Stubbings; David C Baker
Journal:  Am J Manag Care       Date:  2010-05-01       Impact factor: 2.229

2.  Medicare program; changes to the Medicare Advantage and the Medicare prescription drug benefit programs for contract year 2013 and other changes. Final rule with comment period.

Authors: 
Journal:  Fed Regist       Date:  2012-04-12

3.  Numeracy and Medicare Part D: the importance of choice and literacy for numbers in optimizing decision making for Medicare's prescription drug program.

Authors:  Stacey Wood; Yaniv Hanoch; Andrew Barnes; Pi-Ju Liu; Janet Cummings; Chandrima Bhattacharya; Thomas Rice
Journal:  Psychol Aging       Date:  2011-06

4.  The impact of Medicare Part D on hospitalization rates.

Authors:  Christopher C Afendulis; Yulei He; Alan M Zaslavsky; Michael E Chernew
Journal:  Health Serv Res       Date:  2011-02-09       Impact factor: 3.402

5.  Impact of telephone medication therapy management on medication and health-related problems, medication adherence, and Medicare Part D drug costs: a 6-month follow up.

Authors:  Leticia R Moczygemba; Jamie C Barner; Kenneth A Lawson; Carolyn M Brown; Evelyn R Gabrillo; Paul Godley; Michael Johnsrud
Journal:  Am J Geriatr Pharmacother       Date:  2011-08-24

6.  Persistence with biologic therapies in the Medicare coverage gap.

Authors:  Leonardo Tamariz; Claudia L Uribe; Jiacong Luo; John W Hanna; Daniel E Ball; Kelly Krohn; Eric S Meadows
Journal:  Am J Manag Care       Date:  2011-11       Impact factor: 2.229

7.  Age and the purchase of prescription drug insurance by older adults.

Authors:  Helena Szrek; M Kate Bundorf
Journal:  Psychol Aging       Date:  2011-06

8.  Clinically unintended medication switches and inability to prescribe preferred medications under Medicare Part D.

Authors:  Joyce C West; Donald S Rae; Ramin Mojtabai; Maritza Rubio-Stipec; Julie A Kreyenbuhl; Carol L Alter; Stephen Crystal
Journal:  J Psychopharmacol       Date:  2011-06-21       Impact factor: 4.153

9.  Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007.

Authors:  Becky A Briesacher; Yanfang Zhao; Jeanne M Madden; Fang Zhang; Alyce S Adams; Jennifer Tjia; Dennis Ross-Degnan; Jerry H Gurwitz; Stephen B Soumerai
Journal:  Med Care       Date:  2011-09       Impact factor: 2.983

10.  Cost-related nonadherence in the Medicare program: the impact of Part D.

Authors:  James J Kennedy; Matthew Maciejewski; Darren Liu; Elizabeth Blodgett
Journal:  Med Care       Date:  2011-05       Impact factor: 2.983

View more
  4 in total

1.  Pharmaceutical policies used by private health insurance companies in Saudi Arabia.

Authors:  Saleh A Bawazir; Mohammed A Alkudsi; Abdullah S Al Humaidan; Maher A Al Jaser; Larry D Sasich
Journal:  Saudi Pharm J       Date:  2012-11-12       Impact factor: 4.330

Review 2.  Challenges to integrating pharmacogenetic testing into medication therapy management.

Authors:  Susanne B Haga; Nancy M Allen LaPointe; Jivan Moaddeb
Journal:  J Manag Care Spec Pharm       Date:  2015-04

3.  Effect of multiple pharmacy use on medication adherence and drug-drug interactions in older adults with Medicare Part D.

Authors:  Zachary A Marcum; Julia Driessen; Carolyn T Thorpe; Walid F Gellad; Julie M Donohue
Journal:  J Am Geriatr Soc       Date:  2014-01-21       Impact factor: 5.562

4.  Variation in Medication Therapy Management Delivery: Implications for Health Care Policy.

Authors:  Margie E Snyder; Heather A Jaynes; Stephanie A Gernant; Wendy M Lantaff; Karen Suchanek Hudmon; William R Doucette
Journal:  J Manag Care Spec Pharm       Date:  2018-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.